NRG-HN014: Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response Adapted Treatment versus Standard of Care Treat

Back to Results

NRG-HN014

NRG-HN014: Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response Adapted Treatment versus Standard of Care Treatment for Resectable Stage III/IV Cutaneous Squamous Carcinoma